ClinicalTrials.gg
CompletedNCT03589586Updated Mar 18, 2021

Clinical Effectiveness of DermACELL AWM in Subjects With Chronic Venous Leg Ulcers

An interventional study of DermACELL AWM in Venous Leg Ulcer, sponsored by LifeNet Health. Completed at 7 sites in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-18.

Sponsored by LifeNet Health · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies in Varicose Ulcer with a site in United States — 33 open to participants now, 43 under way, 4 of them phase 3. Varicose Ulcer · United States.

Enrollment
48th of 132
100 · median 53
Started
2018
with 7 others
No phase
79 of 155
17 open now
Registered
89th of 155
by date

Among the 155 studies in Varicose Ulcer with a site in United States, this one is the 48th largest by enrollment of the 132 interventional ones that give a count, is one of 8 that started in 2018, is one of 79 with no phase, and was the 89th registered.

Varicose Ulcer

371 studies on the registry are indexed under Varicose Ulcer; 75 are open to participants now.

Browse Varicose Ulcer studies →

Open to participants now

33 of the 155 studies in Varicose Ulcer with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Varicose Ulcer with a site in United States, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, controlled, open-label trial designed to evaluate the safety and efficacy of DermACELL in subjects with a single target chronic venous leg ulcer (VLU).

Read the detailed description

This study is a multicenter, randomized, controlled, open-label trial designed to evaluate the safety and efficacy of DermACELL in subjects with a single target chronic venous leg ulcer (VLU). After eligibility is determined at a screening visit, VLU subjects will be entered into a 2 week run-in period of conventional wound care with moist wound therapy and multilayer compression bandage.

At baseline, those continuing to meet eligibility criteria will be randomized to either DermACELL or conventional care wound management at a ratio of 1:1. The appropriate size of DermACELL will be applied to the wound of subjects in the DermACELL arm. The ADM will be attached with sutures, sterile adhesive strips, or bioadhesive, and covered with a dressing. For subjects in the conventional care wound management arm, the debrided wound will undergo a moist-wound therapy consisting of alginates, foams, or hydrogels, and will be covered with a gauze that is appropriate for the type of wound (moist or dry).

Subsequent study visits will occur every week until 100% re-epithelialization or up to 16 weeks after treatment (whichever comes first).

03

Conditions studied

  • Venous Leg Ulcer

Browse trials for

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been on a stable anti-diabetic treatment for at least 30 days before the baseline visit if the subject has a diagnosis of Type 1 or Type 2 diabetes as defined by the American Diabetes Association
  • Have a full-thickness venous leg ulcer that does not penetrate into the muscle, tendon or bone.
  • Have a single target ulcer
  • Have a wound with an area greater than or equal to 1 cm2 and less than 25 cm2 and a depth less than or equal to 9 mm
  • Have a venous stasis ulcer that has been present for at least 30 days.
  • Have a Clinical severity, Etiology or cause, Anatomy and Pathophysiology ulcer classification (CEAP) Grade C6: an open venous ulcer
  • Have an absence of infection based on Infectious Disease Society of America criteria
  • Have adequate circulation to the affected lower extremity, defined as an Ankle-brachial index (ABI) greater than 0.75.
  • Have the ability to comply with off-loading (if required for specific wound), compression and dressing change requirements
  • Have the ability to understand the requirements of the study, have provided written as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments
  • Have provided written authorization for use and disclosure of protected health information
  • Have a of greater than 6 months

Exclusion criteria

Exclusion Criteria:

  • Be pregnant or lactating
  • Have a venous leg ulcer on the dorsum of the foot or more than 50% of the ulcer is below the malleolus
  • Have circulating exceeding 12% within 90 days of the screening visit
  • Have serum creatinine concentrations of 3.0 mg/dL or greater within 30 days prior to screening
  • Have a sensitivity to either of the following antibiotics: lincomycin, gentamicin, polymyxin B, or vancomycin
  • Have a sensitivity to polysorbate 20, N-lauroyl sarcosinate, benzonase or glycerol
  • Have the wound treated with biomedical or topical growth factors within the previous 30 days before the screening visit
  • Need for any additional concomitant dressing material other than the ones approved for this study
  • Have clinical signs of an infection at the study ulcer site
  • Have the inability to tolerate compression bandage
  • Have a known or suspected disease of the immune system
  • Have an active or untreated or active, uncontrolled connective tissue disease
  • Had a treatment with or chemotherapeutic agents, radiotherapy or systemic less than 30 days before the baseline visit
  • Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement
  • Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the baseline visit
  • Have serum , alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening
  • Have active Charcot disease
  • Have undergone treatment with a living skin equivalent within the last 4 weeks before the screening visit
  • Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot
  • Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    DermACELL AWM + Conventional Care

    DermACELL AWM, acellular dermal matrix, plus conventional wound care- DermACELL AWM will be applied at the Baseline visit. Conventional wound care will include advanced wound dressings and multilayer compression.

    Other: DermACELL AWM

  • No intervention
    Conventional Care

    Conventional wound care will include advanced wound dressings and multilayer compression.

Interventions

  • OtherDermACELL AWM

    DermACELL AWM is a sterile, ready to use acellular dermal matrix

    Also known as: Acellular dermal matrix

06

What researchers measure

Primary outcomes

  1. Healing Rate

    effect of DermACELL on the proportion of chronic venous leg ulcers that have achieved 100% re-epithelialization without drainage or dressing requirements

    Time frame: 16 Weeks

Secondary outcomes

  1. Time to wound closure

    Change in wound area over time

    Time frame: 16 Weeks

07

Study locations

7 sites
  • Arizona Regional Medical Research
    Tucson, Arizona 85710, United States
  • Southern Arizona VA Health Care System Department of Podiatry
    Tucson, Arizona 85723, United States
  • Limb Preservation Platform
    Fresno, California 93710, United States
  • LA Foot and Ankle Clinic
    Los Angeles, California 90057, United States
  • South Florida Podiatry
    Deerfield Beach, Florida 33442, United States
  • Doctors Research Network
    South Miami, Florida 33143, United States
  • Purvis Moyer Foot and Ankle Center
    Rocky Mount, North Carolina 27804, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jan 2021, 30 months.

Of 67 industry-sponsored interventional studies with no phase under Varicose Ulcer, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 30 months is above that.

Counting every sponsor, half of 134 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2018
First posted
Jul 18, 2018
StartActual
Jun 25, 2018
Primary completionActual
Jan 15, 2021
CompletionActual
Mar 15, 2021
Last update
Mar 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03589586
Lead sponsor
LifeNet Health
Responsible party
Sponsor
First posted
Jul 18, 2018
Start date
Jun 25, 2018
Primary completion
Jan 15, 2021
Completion
Mar 15, 2021
Last update
Mar 18, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion